SLC5A2 and chronic kidney disease: The recently published 2024 KDIGO Clinical Practice Guidelines for the Management of CKD strongly recommend treating CKD patients (eGFR > 20 mL/min) with type 2 diabetes (T2D) or hearth failure (HF) with an SGLT2 inhibitor regardless of the presence of albuminuria; the same level of recommendation is indicated for non-diabetic CKD (eGFR > 20 mL/min) with increased albuminuria (>200 mg/g) [15].